{"transactions":[{"id":743255,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:30:03.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":32947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":32947,"derivative":{"exercise_price":14.09,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":32947},"source":{"system":"sec-edgar","filing":"0001193125-26-265908","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526265908/ownership.xml","form_type":"4"}},{"id":1005865,"issuer":{"id":4044,"kind":"organization","name":"Relay Therapeutics, Inc.","symbol":"RLAY"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-06T21:37:03.000Z","date":"2025-11-04","kind":"grant","planned":false,"acquired":true,"shares":207931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments after November 4, 2025, subject to the reporting person's continued service with the Issuer through each vesting date."}],"balance_after":207931,"derivative":{"exercise_price":6.86,"expiration_date":"2035-11-03","underlying":"Common Stock","underlying_shares":207931},"source":{"system":"sec-edgar","filing":"0001193125-25-269790","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312525269790/ownership.xml","form_type":"4"}},{"id":1080681,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T17:15:16.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.73,"underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-099257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099257/ownership.xml","form_type":"4"}},{"id":1080680,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T17:15:16.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.02,"underlying":"Common Stock","underlying_shares":136139},"source":{"system":"sec-edgar","filing":"0000950170-25-099257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099257/ownership.xml","form_type":"4"}},{"id":1083890,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4570,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":106.14,"underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083889,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":63.66,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083888,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":50.64,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083887,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":87.13,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083886,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3188,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":76.24,"underlying":"Common Stock","underlying_shares":3188},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083885,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":96.77,"underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083884,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10909,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":46.02,"underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083883,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10909,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":19.53,"underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083882,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":15.01,"underlying":"Common Stock","underlying_shares":11818},"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1083881,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T19:49:03.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, 2,242 shares of Common Stock held by the Reporting Person were cancelled and automatically converted into the right to receive the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069392","document":"tm2521348-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000110465925069392/tm2521348-5_4seq1.xml","form_type":"4"}},{"id":1102359,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T16:20:56.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":3902,"price":12812,"value":49992424.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":6144,"source":{"system":"sec-edgar","filing":"0001415889-25-018069","document":"form4-06242025_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588925018069/form4-06242025_080653.xml","form_type":"4"}},{"id":1119864,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T17:01:02.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":42200,"derivative":{"exercise_price":5.73,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-083233","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025083233/ownership.xml","form_type":"4"}},{"id":1353811,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-20","kind":"exercise","planned":true,"acquired":false,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on June 24, 2020 and is fully vested as of the transaction date."}],"balance_after":3188,"derivative":{"exercise_price":76.24,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1353810,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-20","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on June 21, 2018 and is fully vested as of the transaction date."}],"balance_after":0,"derivative":{"exercise_price":69.79,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1353809,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-21","kind":"sale","planned":true,"acquired":false,"shares":9824,"price":94.87,"value":932002.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":2242,"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1353808,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-20","kind":"sale","planned":true,"acquired":false,"shares":213,"price":94.99,"value":20232.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is an average price. The shares were sold in multiple transactions ranging from $94.74 to $95.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4)."}],"balance_after":12066,"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1353807,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-20","kind":"sale","planned":true,"acquired":false,"shares":5287,"price":94.24,"value":498246.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is an average price. The shares were sold in multiple transactions ranging from $93.74 to $94.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3)."}],"balance_after":12279,"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1353806,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-20","kind":"sale","planned":true,"acquired":false,"shares":4500,"price":93.15,"value":419175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is an average price. The shares were sold in multiple transactions ranging from $92.71 to $93.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2)."}],"balance_after":17566,"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1353805,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-20","kind":"exercise","planned":true,"acquired":true,"shares":1312,"price":76.24,"value":100026.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":22066,"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1353804,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-22T16:47:52.000Z","date":"2024-11-20","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":69.79,"value":523425.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":20754,"source":{"system":"sec-edgar","filing":"0001415889-24-027545","document":"form4-11222024_091148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924027545/form4-11222024_091148.xml","form_type":"4"}},{"id":1467319,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-28T07:45:05.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":136139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":136139,"derivative":{"exercise_price":5.02,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":136139},"source":{"system":"sec-edgar","filing":"0000950170-24-078780","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017024078780/ownership.xml","form_type":"4"}},{"id":1478483,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T17:37:30.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":4570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":4570,"derivative":{"exercise_price":106.14,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001415889-24-016985","document":"form4-06142024_090625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924016985/form4-06142024_090625.xml","form_type":"4"}},{"id":1478482,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T17:37:30.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":2242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":13254,"source":{"system":"sec-edgar","filing":"0001415889-24-016985","document":"form4-06142024_090625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588924016985/form4-06142024_090625.xml","form_type":"4"}},{"id":1610682,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-29T21:26:53.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":false,"shares":120383,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":240767,"derivative":{"underlying":"Common Stock","underlying_shares":120383},"source":{"system":"sec-edgar","filing":"0001127602-24-007612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224007612/form4.xml","form_type":"4"}},{"id":1610681,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-29T21:26:53.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":false,"shares":91364,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":91363,"derivative":{"underlying":"Common Stock","underlying_shares":91364},"source":{"system":"sec-edgar","filing":"0001127602-24-007612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224007612/form4.xml","form_type":"4"}},{"id":1610680,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-29T21:26:53.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":false,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001127602-24-007612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224007612/form4.xml","form_type":"4"}},{"id":1610679,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-29T21:26:53.000Z","date":"2024-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":61371,"price":2.62,"value":160792.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":1098068,"source":{"system":"sec-edgar","filing":"0001127602-24-007612","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224007612/form4.xml","form_type":"4"}},{"id":1610678,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-29T21:26:53.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":true,"shares":120383,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":1159439,"source":{"system":"sec-edgar","filing":"0001127602-24-007612","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224007612/form4.xml","form_type":"4"}},{"id":1610677,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-29T21:26:53.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":true,"shares":91364,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":1039056,"source":{"system":"sec-edgar","filing":"0001127602-24-007612","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224007612/form4.xml","form_type":"4"}},{"id":1610676,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-29T21:26:53.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":947692,"source":{"system":"sec-edgar","filing":"0001127602-24-007612","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224007612/form4.xml","form_type":"4"}},{"id":1649928,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T21:12:02.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":770420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":770420,"derivative":{"exercise_price":2.15,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":770420},"source":{"system":"sec-edgar","filing":"0001127602-24-004455","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224004455/form4.xml","form_type":"4"}},{"id":1649927,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-12T21:12:02.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":770420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":770420,"derivative":{"underlying":"Common Stock","underlying_shares":770420},"source":{"system":"sec-edgar","filing":"0001127602-24-004455","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224004455/form4.xml","form_type":"4"}},{"id":1737414,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-17T21:55:09.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":90000,"price":1.0533,"value":94797.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.05 to $1.06 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Coats hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected."}],"balance_after":914359,"source":{"system":"sec-edgar","filing":"0001127602-23-027850","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223027850/form4.xml","form_type":"4"}},{"id":1744512,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-13T22:31:49.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.01,"value":10100.0,"ownership":{"direct":true},"balance_after":824359,"source":{"system":"sec-edgar","filing":"0001127602-23-027279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223027279/form4.xml","form_type":"4"}},{"id":1842248,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-29T20:13:50.000Z","date":"2023-06-29","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.16,"value":21600.0,"ownership":{"direct":true},"balance_after":814359,"source":{"system":"sec-edgar","filing":"0001127602-23-019560","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223019560/form4.xml","form_type":"4"}},{"id":1844530,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-26T20:04:07.000Z","date":"2023-06-26","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.1792,"value":21792.0,"ownership":{"direct":true},"balance_after":804359,"source":{"system":"sec-edgar","filing":"0001127602-23-019405","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223019405/form4.xml","form_type":"4"}},{"id":1844529,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-26T20:04:07.000Z","date":"2023-06-23","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.495,"value":24950.0,"ownership":{"direct":true},"balance_after":794359,"source":{"system":"sec-edgar","filing":"0001127602-23-019405","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223019405/form4.xml","form_type":"4"}},{"id":1844872,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T19:04:06.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"price":0,"reported_value":5300,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"derivative":{"exercise_price":63.66,"expiration_date":"2032-06-21","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001415889-23-010259","document":"form4-06232023_110601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923010259/form4-06232023_110601.xml","form_type":"4"}},{"id":1844871,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T19:04:06.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":11012,"source":{"system":"sec-edgar","filing":"0001415889-23-010259","document":"form4-06232023_110601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588923010259/form4-06232023_110601.xml","form_type":"4"}},{"id":1846893,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-22T20:01:14.000Z","date":"2023-06-22","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":2.31,"value":92400.0,"ownership":{"direct":true},"balance_after":784359,"source":{"system":"sec-edgar","filing":"0001127602-23-019231","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223019231/form4.xml","form_type":"4"}},{"id":1849762,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T17:00:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":26642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":26642,"derivative":{"exercise_price":19.84,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":26642},"source":{"system":"sec-edgar","filing":"0001209191-23-038467","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919123038467/doc4.xml","form_type":"4"}},{"id":1984567,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-01T21:46:57.000Z","date":"2023-02-28","kind":"exercise","acquired":false,"shares":91363,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":182727,"derivative":{"underlying":"Common Stock","underlying_shares":91363},"source":{"system":"sec-edgar","filing":"0001127602-23-007915","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223007915/form4.xml","form_type":"4"}},{"id":1984566,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-01T21:46:57.000Z","date":"2023-02-28","kind":"exercise","acquired":false,"shares":33334,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":33333,"derivative":{"underlying":"Common Stock","underlying_shares":33334},"source":{"system":"sec-edgar","filing":"0001127602-23-007915","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223007915/form4.xml","form_type":"4"}},{"id":1984565,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-01T21:46:57.000Z","date":"2023-02-28","kind":"exercise","acquired":false,"shares":84630,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":84630},"source":{"system":"sec-edgar","filing":"0001127602-23-007915","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223007915/form4.xml","form_type":"4"}},{"id":1984564,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-01T21:46:57.000Z","date":"2023-02-28","kind":"tax_withholding","acquired":false,"shares":50971,"price":2.17,"value":110607.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":744359,"source":{"system":"sec-edgar","filing":"0001127602-23-007915","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223007915/form4.xml","form_type":"4"}},{"id":1984563,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-01T21:46:57.000Z","date":"2023-02-28","kind":"exercise","acquired":true,"shares":91363,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":795330,"source":{"system":"sec-edgar","filing":"0001127602-23-007915","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223007915/form4.xml","form_type":"4"}},{"id":1984562,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-01T21:46:57.000Z","date":"2023-02-28","kind":"exercise","acquired":true,"shares":33334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":703967,"source":{"system":"sec-edgar","filing":"0001127602-23-007915","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223007915/form4.xml","form_type":"4"}},{"id":1984561,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-01T21:46:57.000Z","date":"2023-02-28","kind":"exercise","acquired":true,"shares":84630,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":670633,"source":{"system":"sec-edgar","filing":"0001127602-23-007915","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223007915/form4.xml","form_type":"4"}},{"id":2020596,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-13T21:55:58.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":1083440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":1083440,"derivative":{"exercise_price":2.43,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":1083440},"source":{"system":"sec-edgar","filing":"0001127602-23-004919","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223004919/form4.xml","form_type":"4"}},{"id":2020595,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-13T21:55:58.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":361150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":361150,"derivative":{"underlying":"Common Stock","underlying_shares":361150},"source":{"system":"sec-edgar","filing":"0001127602-23-004919","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223004919/form4.xml","form_type":"4"}},{"id":2191023,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-09T17:05:20.000Z","date":"2022-08-08","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date of the option is the grant date. The shares of common stock underlying the option are scheduled to vest in equal monthly installments through August 8, 2025, subject to the Reporting Person's continued service."}],"balance_after":31000,"derivative":{"exercise_price":27.17,"expiration_date":"2032-08-07","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001209191-22-045039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919122045039/doc4.xml","form_type":"4"}},{"id":2218488,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-30T21:57:01.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":50.64,"expiration_date":"2032-06-21","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001415889-22-007133","document":"form4-06302022_060652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922007133/form4-06302022_060652.xml","form_type":"4"}},{"id":2218487,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-30T21:57:01.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":8412,"source":{"system":"sec-edgar","filing":"0001415889-22-007133","document":"form4-06302022_060652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000141588922007133/form4-06302022_060652.xml","form_type":"4"}},{"id":2369700,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-01T00:11:15.000Z","date":"2022-02-28","kind":"exercise","acquired":false,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":66667,"derivative":{"underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001127602-22-007167","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222007167/form4.xml","form_type":"4"}},{"id":2369699,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-01T00:11:15.000Z","date":"2022-02-28","kind":"exercise","acquired":false,"shares":84630,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":84630,"derivative":{"underlying":"Common Stock","underlying_shares":84630},"source":{"system":"sec-edgar","filing":"0001127602-22-007167","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222007167/form4.xml","form_type":"4"}},{"id":2369698,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-01T00:11:15.000Z","date":"2022-02-28","kind":"exercise","acquired":false,"shares":79380,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":79380},"source":{"system":"sec-edgar","filing":"0001127602-22-007167","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222007167/form4.xml","form_type":"4"}},{"id":2369697,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-01T00:11:15.000Z","date":"2022-02-28","kind":"tax_withholding","acquired":false,"shares":48053,"price":2.85,"value":136951.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":586003,"source":{"system":"sec-edgar","filing":"0001127602-22-007167","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222007167/form4.xml","form_type":"4"}},{"id":2369696,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-01T00:11:15.000Z","date":"2022-02-28","kind":"exercise","acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":634056,"source":{"system":"sec-edgar","filing":"0001127602-22-007167","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222007167/form4.xml","form_type":"4"}},{"id":2369695,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-01T00:11:15.000Z","date":"2022-02-28","kind":"exercise","acquired":true,"shares":84630,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":600723,"source":{"system":"sec-edgar","filing":"0001127602-22-007167","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222007167/form4.xml","form_type":"4"}},{"id":2369694,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-01T00:11:15.000Z","date":"2022-02-28","kind":"exercise","acquired":true,"shares":79380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":516093,"source":{"system":"sec-edgar","filing":"0001127602-22-007167","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222007167/form4.xml","form_type":"4"}},{"id":2398984,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-14T21:05:27.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":274090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":274090,"derivative":{"underlying":"Common Stock","underlying_shares":274090},"source":{"system":"sec-edgar","filing":"0001127602-22-004760","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222004760/form4.xml","form_type":"4"}},{"id":2398983,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-14T21:05:27.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":822280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":822280,"derivative":{"exercise_price":3.2,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":822280},"source":{"system":"sec-edgar","filing":"0001127602-22-004760","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760222004760/form4.xml","form_type":"4"}},{"id":2680441,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:19:26.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022."}],"balance_after":4500,"derivative":{"exercise_price":87.13,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-21-006419","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021006419/edgar.xml","form_type":"4"}},{"id":2680440,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T16:19:26.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":5812,"source":{"system":"sec-edgar","filing":"0001179110-21-006419","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911021006419/edgar.xml","form_type":"4"}},{"id":2821838,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":84630,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":169260,"derivative":{"underlying":"Common Stock","underlying_shares":84630},"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821837,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":79380,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter."}],"balance_after":79380,"derivative":{"underlying":"Common Stock","underlying_shares":79380},"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821836,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":23513,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23513},"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821835,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":5362,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5362},"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821834,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":55038,"price":7.19,"value":395723.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":436713,"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821833,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":84630,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":491751,"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821832,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":79380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":407121,"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821831,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":23513,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":327741,"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2821830,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-02T21:57:05.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":5362,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":304228,"source":{"system":"sec-edgar","filing":"0001127602-21-008768","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221008768/form4.xml","form_type":"4"}},{"id":2860066,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-16T21:10:49.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":300000,"derivative":{"exercise_price":8.38,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001127602-21-005833","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221005833/form4.xml","form_type":"4"}},{"id":2860065,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2021-02-16T21:10:49.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001127602-21-005833","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760221005833/form4.xml","form_type":"4"}},{"id":3098260,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T16:11:03.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021."}],"balance_after":4500,"derivative":{"exercise_price":76.24,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-20-007794","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007794/edgar.xml","form_type":"4"}},{"id":3098259,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-26T16:11:03.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-007794","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007794/edgar.xml","form_type":"4"}},{"id":3101552,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T16:19:51.000Z","date":"2020-06-19","kind":"exercise","acquired":false,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-20-007722","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007722/edgar.xml","form_type":"4"}},{"id":3101551,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T16:19:51.000Z","date":"2020-06-19","kind":"exercise","acquired":true,"shares":1312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1312,"source":{"system":"sec-edgar","filing":"0001179110-20-007722","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1597264/000117911020007722/edgar.xml","form_type":"4"}},{"id":3233955,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":false,"shares":79380,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter."}],"balance_after":158760,"derivative":{"underlying":"Common Stock","underlying_shares":79380},"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233954,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":false,"shares":23514,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter."}],"balance_after":23513,"derivative":{"underlying":"Common Stock","underlying_shares":23514},"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233953,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":false,"shares":5363,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter."}],"balance_after":5362,"derivative":{"underlying":"Common Stock","underlying_shares":5363},"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233952,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":false,"shares":8390,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8390},"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233951,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":45320,"price":2.77,"value":125536.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto."}],"balance_after":298866,"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233950,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":true,"shares":79380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":344186,"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233949,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":true,"shares":23514,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":264806,"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233948,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":true,"shares":5363,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":241292,"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3233947,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-03T21:11:05.000Z","date":"2020-02-28","kind":"exercise","acquired":true,"shares":8390,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":235929,"source":{"system":"sec-edgar","filing":"0001127602-20-008948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220008948/form4.xml","form_type":"4"}},{"id":3282935,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-10T21:06:11.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":761660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":761660,"derivative":{"exercise_price":3.31,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":761660},"source":{"system":"sec-edgar","filing":"0001127602-20-004589","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220004589/form4.xml","form_type":"4"}},{"id":3282934,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-02-10T21:06:11.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":253890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":253890,"derivative":{"underlying":"Common Stock","underlying_shares":253890},"source":{"system":"sec-edgar","filing":"0001127602-20-004589","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760220004589/form4.xml","form_type":"4"}},{"id":3410056,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-19T20:28:29.000Z","date":"2019-09-18","kind":"purchase","acquired":true,"shares":50000,"price":3.1,"value":155000.0,"ownership":{"direct":true},"balance_after":227539,"source":{"system":"sec-edgar","filing":"0001127602-19-028814","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028814/form4.xml","form_type":"4"}},{"id":3411152,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-18T20:39:50.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":40290,"price":3.13,"value":126107.7,"ownership":{"direct":true},"balance_after":177539,"source":{"system":"sec-edgar","filing":"0001127602-19-028744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028744/form4.xml","form_type":"4"}},{"id":3411151,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-18T20:39:50.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":277,"price":3.1296,"value":866.8992,"ownership":{"direct":true},"balance_after":137249,"source":{"system":"sec-edgar","filing":"0001127602-19-028744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028744/form4.xml","form_type":"4"}},{"id":3411150,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-18T20:39:50.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":6333,"price":3.12,"value":19758.96,"ownership":{"direct":true},"balance_after":136972,"source":{"system":"sec-edgar","filing":"0001127602-19-028744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028744/form4.xml","form_type":"4"}},{"id":3411149,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-18T20:39:50.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":3000,"price":3.119,"value":9357.0,"ownership":{"direct":true},"balance_after":130639,"source":{"system":"sec-edgar","filing":"0001127602-19-028744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028744/form4.xml","form_type":"4"}},{"id":3411148,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":39692,"kind":"person","name":"COATS LONNEL","position":1,"cik":"0001612528","reported_name":"COATS LONNEL","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-09-18T20:39:50.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":100,"price":3.125,"value":312.5,"ownership":{"direct":true},"balance_after":127639,"source":{"system":"sec-edgar","filing":"0001127602-19-028744","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760219028744/form4.xml","form_type":"4"}}],"next_cursor":"2019-09-18T20:39:50.000000Z,3411148"}